Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Jamie Bates, Saritha Kusam, Stacey Tannheimer, Astrid Clarke, Thomas Kenney, David Breckenridge and Daniel Tumas | ||||||||||||
Title | Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/128/22/5104?sso-checked=true | ||||||||||||
Abstract Text | Blood 2016 128:5104 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GS-5829 | Alobresib|GS5829|GS 5829 | BET Inhibitor (Pan) 32 | Alobresib (GS-5829) is a BET bromodomain inhibitor, potentially resulting in inhibition of cell growth and apoptotic activity (Blood 2016 128:5104, PMID: 29941483, PMID: 31862959). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|